Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Gastroenterology · Type 1 Gastric Neuroendocrine Tumor

Gastric NETs vs Stomach Cancer: What's the Difference?

At a Glance

In autoimmune gastritis, a Type 1 gastric neuroendocrine tumor (gNET) is entirely different from regular stomach cancer. While standard stomach cancer (adenocarcinoma) is aggressive, Type 1 gNETs are slow-growing, highly treatable, and easily removed during a routine endoscopy.

When you have autoimmune gastritis (AIG), seeing the word “tumor” on a pathology report can be terrifying. If your doctor mentions a gastric neuroendocrine tumor (gNET)—a type of tumor that forms in hormone-producing cells—you might understandably worry that you have “regular” stomach cancer. However, in the context of AIG, these are two entirely different conditions with very different behaviors, risks, and treatments.

The short answer is that the specific type of gNET caused by AIG (known as a Type 1 gNET) is generally slow-growing, highly treatable, and carries an excellent prognosis [1][2]. In contrast, regular stomach cancer (gastric adenocarcinoma) is a more aggressive disease that behaves differently and requires more intensive treatment [2][3].

How They Develop Differently

Type 1 Gastric NETs:
These small tumors are a direct result of the immune system’s attack on your stomach. In AIG, your body destroys the cells that make stomach acid [4]. Because your stomach acid is so low, your body tries to fix the problem by pumping out high levels of a hormone called gastrin [5]. Over time, this chronic high gastrin overstimulates specific cells in the stomach lining (called ECL cells), causing them to grow and multiply [6]. This chain reaction—no acid, high gastrin, cell overgrowth—is what eventually forms a Type 1 gNET [4].

Note: Pathology reports sometimes just say “gNET” without a number. Type 1 is specifically the kind driven by high gastrin in AIG. Other types (like Type 2 or Type 3) have different causes and behaviors, so it is important to confirm with your doctor that yours is a Type 1.

Gastric Adenocarcinoma (“Regular” Stomach Cancer):
Adenocarcinoma develops from the glandular cells of the stomach lining. While having AIG does slightly increase your risk for this type of cancer due to long-term inflammation and changes to the stomach tissue [5], it is much less common in pure AIG compared to Type 1 gNETs, especially if you have never been infected with H. pylori bacteria [7].

Differences in Aggressiveness and Symptoms

  • Behavior: Type 1 gNETs are known as “indolent” or slow-growing [2]. They are typically well-differentiated, meaning the cells look very much like normal cells, and they rarely spread to other parts of the body [8][9]. Gastric adenocarcinoma is much more aggressive and has a higher potential to spread [3].
  • Symptoms: Type 1 gNETs are almost always “silent,” meaning they do not typically cause pain, nausea, or other symptoms on their own. They are usually only discovered during a routine endoscopy.
  • Outlook: Because Type 1 gNETs are so slow-growing and non-aggressive, they have a very favorable prognosis [1]. While they can recur (come back in the stomach after being removed), they are easily managed and rarely impact life expectancy [10][11].

Differences in Treatment

Because they behave so differently, doctors treat Type 1 gNETs and adenocarcinomas in completely different ways.

  • Treating Type 1 gNETs: These are usually managed very conservatively. Most often, a gastroenterologist will simply remove the small tumors during a routine upper endoscopy (a procedure called endoscopic resection) [12][13]. While small tumors are easily removed this way, larger tumors (usually over 1 to 2 centimeters) may occasionally require surgery [12]. Afterward, you will need regular follow-up endoscopies (often every 1 to 2 years, depending on your doctor’s advice) to monitor for any new growths [10]. If the tumors frequently recur, doctors might use a medication called a somatostatin analog to help lower gastrin levels [14][15].
  • Treating Adenocarcinoma: Because of its aggressive nature, regular stomach cancer typically requires major surgery, such as removing part or all of the stomach (gastrectomy), often combined with lymph node removal, chemotherapy, or radiation [16][17].

The Bottom Line

If you are diagnosed with a Type 1 gNET as a result of autoimmune gastritis, it is important to know that this is not the same as aggressive stomach cancer. While you will need regular monitoring to keep an eye on your stomach lining, Type 1 gNETs are highly manageable and behave in a very slow-growing, non-aggressive way.

Common questions in this guide

What is a Type 1 gastric neuroendocrine tumor (gNET)?
A Type 1 gNET is a small, slow-growing tumor in the stomach lining. It develops when autoimmune gastritis destroys acid-producing cells, causing the body to overproduce the hormone gastrin.
Is a gastric NET the same as stomach cancer?
No, a Type 1 gNET is very different from standard stomach cancer, also known as gastric adenocarcinoma. While regular stomach cancer is aggressive and requires intensive treatment, Type 1 gNETs are slow-growing, rarely spread, and have an excellent prognosis.
How is a Type 1 gastric NET treated?
Most Type 1 gNETs are managed conservatively and can be completely removed during a routine upper endoscopy. After removal, you will need regular follow-up endoscopies to monitor for any new growths.
How do I know if my tumor is a Type 1 gNET?
Your doctor can confirm the tumor type by reviewing the pathology report from your stomach biopsy. It is crucial to verify that it is a Type 1 gNET linked to autoimmune gastritis, because other types of gNETs require different management.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you confirm from my pathology report that my tumor is specifically a Type 1 gNET related to my autoimmune gastritis, rather than a different type?
  2. 2.What was the grade and size of the gNET, and were you able to remove it completely during the endoscopy?
  3. 3.How often should we schedule my follow-up endoscopies to monitor for new gNETs or other stomach changes?
  4. 4.Do my past biopsy results show any history of an H. pylori infection, and how does that affect my long-term monitoring plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Management of Gastric Neuroendocrine Tumors: A Review.

    Sok C, Ajay PS, Tsagkalidis V, et al.

    Annals of surgical oncology 2024; (31(3)):1509-1518 doi:10.1245/s10434-023-14712-9.

    PMID: 38062290
  2. 2

    Gastric neuroendocrine neoplasms: A review.

    Köseoğlu H, Duzenli T, Sezikli M

    World journal of clinical cases 2021; (9(27)):7973-7985 doi:10.12998/wjcc.v9.i27.7973.

    PMID: 34621854
  3. 3

    Comparison of Survival and Patterns of Recurrence in Gastric Neuroendocrine Carcinoma, Mixed Adenoneuroendocrine Carcinoma, and Adenocarcinoma.

    Lin J, Zhao Y, Zhou Y, et al.

    JAMA network open 2021; (4(7)):e2114180 doi:10.1001/jamanetworkopen.2021.14180.

    PMID: 34313744
  4. 4

    Unmasking the high-risk phenotype in autoimmune gastritis: A pathologist's roadmap for the clinician.

    Wang CL, Zeng M, Luo Y

    World journal of gastroenterology 2025; (31(48)):115244 doi:10.3748/wjg.v31.i48.115244.

    PMID: 41480315
  5. 5

    The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective.

    Massironi S, Zilli A, Elvevi A, Invernizzi P

    Autoimmunity reviews 2019; (18(3)):215-222 doi:10.1016/j.autrev.2018.08.011.

    PMID: 30639639
  6. 6

    Progression From Antral G-Cell Hyperplasia to Gastric Neuroendocrine Tumor in a Patient With Autoimmune Gastritis.

    Brown P, Tetali B, Suresh S, Varma A

    ACG case reports journal 2021; (8(8)):e00649 doi:10.14309/crj.0000000000000649.

    PMID: 34476276
  7. 7

    Autoimmune Gastritis in Korean Patients with Gastric Tumors: Clinicopathologic Correlations and Diagnostic Histological Features.

    Ahn S, Kim TS, Kushima R, et al.

    Gut and liver 2025; (19(2)):177-188 doi:10.5009/gnl240223.

    PMID: 39506312
  8. 8

    Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients.

    Wang X, Jiao J, Huh WJ, Zhang X

    Archives of pathology & laboratory medicine 2025; (150(1)):81-87 doi:10.5858/arpa.2025-0030-OA.

    PMID: 40509896
  9. 9

    Clinical characteristics and long-term prognosis of type 1 gastric neuroendocrine tumors in a large Japanese national cohort.

    Namikawa K, Kamada T, Fujisaki J, et al.

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2023; (35(6)):757-766 doi:10.1111/den.14529.

    PMID: 36721901
  10. 10

    Gastric neuroendocrine tumors: 20-Year experience in a reference center.

    Ravizza D, Giunta M, Sala I, et al.

    Journal of neuroendocrinology 2024; (36(12)):e13440 doi:10.1111/jne.13440.

    PMID: 39191460
  11. 11

    Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.

    Chen YY, Guo WJ, Shi YF, et al.

    BMC gastroenterology 2023; (23(1)):440 doi:10.1186/s12876-023-03079-6.

    PMID: 38097952
  12. 12

    Clinical Outcomes of Endoscopic Treatment for Type 1 Gastric Neuroendocrine Tumor.

    Noh JH, Kim DH, Yoon H, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(10)):2495-2502 doi:10.1007/s11605-021-04997-0.

    PMID: 33825119
  13. 13

    Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China.

    Chen X, Li B, Wang S, et al.

    Scandinavian journal of gastroenterology 2019; (54(3)):384-389 doi:10.1080/00365521.2019.1588367.

    PMID: 31037980
  14. 14

    Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.

    Rossi RE, Invernizzi P, Mazzaferro V, Massironi S

    United European gastroenterology journal 2020; (8(2)):140-147 doi:10.1177/2050640619890465.

    PMID: 32213066
  15. 15

    Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.

    Huang J, Liu H, Yang D, et al.

    Chinese medical journal 2024; (137(6)):720-728 doi:10.1097/CM9.0000000000003029.

    PMID: 38384175
  16. 16

    [A 3mm Gastric Neuroendocrine Tumor That Metastasized to a Lymph Node].

    Fukui Y, Kato Y, Okazaki Y, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2018; (45(13)):1839-1841.

    PMID: 30692371
  17. 17

    Neuroendocrine Tumors of the Stomach.

    Corey B, Chen H

    The Surgical clinics of North America 2017; (97(2)):333-343 doi:10.1016/j.suc.2016.11.008.

    PMID: 28325190

This page explains the differences between gastric NETs and stomach cancer for educational purposes only. Always consult your gastroenterologist or oncologist to discuss your specific pathology report and treatment options.

Get notified when new evidence is published on autoimmune gastritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.